Skip to main
  1. Stocks
  2. Definium Therapeutics Inc
  3. Forecast
DFTX

DFTX Stock Forecast & Price Target

DFTX Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Definium Therapeutics is viewed favorably because DT120 has produced three consecutive Phase 3 wins across GAD and MDD, including a 5.1-point placebo-adjusted HAM-A improvement in PANORAMA and an 8.1-point placebo-adjusted MADRS improvement in EMERGE, with a clean safety profile and rapid onset. The company’s Breakthrough Therapy Designation in both indications, plus a scheduled pre-NDA meeting in 4Q26 and NDA filing anticipated in 1H27, strengthens the regulatory path and raises the possibility of a broader dual-indication label. Survey work and updated modeling suggest a combined ~$2.3B opportunity across GAD and MDD, while the stock trading near cash implies the market may be underpricing the commercial upside of a differentiated, single-dose psychiatry franchise.

Bears say

Definium Therapeutics is viewed negatively because its lead DT120 ODT remains exposed to major clinical risk, including the possibility that early anxiety signals are not reproducible and that long-term safety is not well known. The stock also faces meaningful regulatory and commercialization hurdles beyond FDA approval, including DEA rescheduling, REMS requirements, stigma, and slow physician adoption, any of which could limit market access even after the four Phase 3 trials. In addition, the company lacks a composition-of-matter patent for LSD and may have to rely mainly on regulatory exclusivity, while still facing the risk of being unable to fund operations with no commercial products.

DFTX has been analyzed by 16 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Definium Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

DFTX Analyst Forecast & Price Prediction

Get the latest DFTX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in DFTX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Definium Therapeutics Inc (DFTX) Forecast

Analysts have given DFTX a Buy based on their latest research and market trends.

According to 16 analysts, DFTX has a Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $65.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $65.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Definium Therapeutics Inc (DFTX)


DFTX Analyst Forecast & Price Prediction

Get the latest DFTX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in DFTX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover DFTX stock data and trends